In March of 2017, Immune Therapeutics, Inc. announced that it signed a Memorandum of Understanding (“MOU”) for distribution of its patented Lodonal™ in Kenya.
Immune Therapeutics, Inc
Announces First Sales & Shipment of Lodonal;
Receives Trademark and Patent Approval
From Federal Republic of Nigeria
Immune Therapeutics Announces
Exclusive Agreement for Sale of Lodonal in Kenya
Valued at Over $31 Million
Immune Therapeutics Announces
NAFDAC Approval for Marketing & Distribution of Lodonal™
Immune Therapeutics Emerges as a Key Player in Immunotherapy Field
research & immunology
Discover more about
our research and technology
research and investigation
Investing in a better and healthier
world today to see it tomorrow
CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack cancer tumors
Lodonal Nigeria Study
Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has recently approved Immune Therapeutics, Inc. patented Lodonal™ as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator.
In April of 2016, Immune Therapeutics, Inc. entered into a binding letter of intent with Super T-Cell Cancer Company, a newly formed Chinese corporation, for the acquisition of Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and clinical data.
In January 2015, The Jack Brewer Foundation (JBF Worldwide)(insert link) and Immune Therapeutics, Inc. announced first-of-its-kind donation program to improve access to treatment to prevent cervical cancer that until now has been unavailable to the women of Malawi, Africa.
Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has recently approved its Immune Therapeutics, Inc. patented Lodonal™ as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator.
In October 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, announced an agreement to co-develop new cancer drugs based on Immune Therapeutics’ patents involving MENK
ORLANDO, Fla., Feb. 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal” and IRT-101 “MENK”) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs, today announced the company has shipped its initial order of Lodonal to AHAR Pharma in Nigeria.
In addition, IMUN has received both trademark and patent approval from the Federal Republic of Nigeria giving the Company ironclad protection of its ideas, inventions, designs, and trade secrets while also ensuring IMUN legal rights are not infringed upon.
ORLANDO, Fla., Nov. 30, 2017 /PRNewswire/ -- Immune Therapeutics, Inc. (OTCQB: IMUN), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products to alleviate human suffering in HIV/AIDS, cancer, pain, opportunistic infections and autoimmune and inflammatory disease areas today provided the following letter to shareholders:
We have had a lot of developments since our last Shareholder update. We know many of you have been asking for updates and we are excited to share the most recent news. We apologize for being relatively quiet this past year, but we will now make it a priority to have consistent updates for our shareholders.
We know results will speak for themselves and we have certainly had our challenges, but I am extremely excited and optimistic about our future. Creating and developing the assets that we currently have has taken a considerable amount of time, dedication, effort and a "never give-up" attitude. With many pieces of the puzzle now together, I believe that we are poised to embark on a journey that will transform Immune Therapeutics and propel us to success.
LDN holds great promise for the millions of people worldwide with autoimmune diseases or central nervous system disorders or who face a deadly cancer. It could prove to be the first low-cost, easy to administer, and side-effect-free therapy for Cancer, HIV/AIDS, MS and Crohn’s disease
Providing safe, effective and innovative pharmaceutical products that contribute to the well-being and health of the people since 1972